Century Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Century Therapeutics Stock-Based Compensation Growth & History (IPSC)
Century Therapeutics's stock-based compensation was $6.8M for fiscal 2025.
View full Century Therapeutics company overviewCentury Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.8M | −$5.8M | −46.09% |
| 2024 | 2024-12-31 | $12.7M | −$1.9M | −13.23% |
| 2023 | 2023-12-31 | $14.6M | $4.0M | +37.05% |
| 2022 | 2022-12-31 | $10.7M | $6.0M | +128.85% |
| 2021 | 2021-12-31 | $4.7M | $3.8M | +432.19% |
| 2020 | 2020-12-31 | $876,000 | — | — |
Century Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.9M | −$272,000 | −12.24% |
| Q1 2026 | 2026-03-31 | $1.4M | −$981,000 | −40.44% |
| Q4 2025 | 2025-12-31 | $1.3M | −$1.4M | −51.13% |
| Q3 2025 | 2025-09-30 | $892,000 | −$2.4M | −73.12% |
| Q2 2025 | 2025-06-30 | $2.2M | −$1.3M | −36.57% |
| Q1 2025 | 2025-03-31 | $2.4M | −$781,000 | −24.35% |
| Q4 2024 | 2024-12-31 | $2.7M | −$902,000 | −25.32% |
| Q3 2024 | 2024-09-30 | $3.3M | −$660,000 | −16.59% |
| Q2 2024 | 2024-06-30 | $3.5M | $218,000 | +6.64% |
| Q1 2024 | 2024-03-31 | $3.2M | −$590,000 | −15.54% |
| Q4 2023 | 2023-12-31 | $3.6M | $830,000 | +30.38% |
| Q3 2023 | 2023-09-30 | $4.0M | $1.2M | +42.79% |
| Q2 2023 | 2023-06-30 | $3.3M | $514,000 | +18.55% |
| Q1 2023 | 2023-03-31 | $3.8M | $1.4M | +59.54% |
| Q4 2022 | 2022-12-31 | $2.7M | $1.1M | +66.99% |
| Q3 2022 | 2022-09-30 | $2.8M | $1.6M | +128.36% |
| Q2 2022 | 2022-06-30 | $2.8M | $1.1M | +61.95% |
| Q1 2022 | 2022-03-31 | $2.4M | $2.3M | +2405.26% |
| Q4 2021 | 2021-12-31 | $1.6M | — | — |
| Q3 2021 | 2021-09-30 | $1.2M | $1.1M | +747.22% |
| Q2 2021 | 2021-06-30 | $1.7M | $1.6M | +1148.91% |
| Q1 2021 | 2021-03-31 | $95,000 | — | — |
| Q3 2020 | 2020-09-30 | $144,000 | — | — |
| Q2 2020 | 2020-06-30 | $137,000 | — | — |
Century Therapeutics stock-based compensation trends
Over the last five fiscal years, Century Therapeutics's stock-based compensation increased from $876,000 to $6.8M, a change of $6.0M. The latest reported quarter, Q2 2026, shows $1.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Century Therapeutics source filings ↗